DEF: Alkermes Schedules 2026 Annual Meeting, Proposes Director Elections

Alkermes plc has announced its 2026 Annual General Meeting of Shareholders, scheduled for May 20, 2026, to elect directors, approve executive compensation, ratify auditor appointment, and renew board authorities.

Summary

• Alkermes plc is holding its 2026 Annual General Meeting of Shareholders on May 20, 2026, in Dublin, Ireland.
• The meeting agenda includes the election of nine director nominees for one-year terms.
• Shareholders will vote on a non-binding advisory basis for the compensation of named executive officers.
• The appointment of PricewaterhouseCoopers LLP as the independent auditor will be ratified on a non-binding advisory basis, with the Audit and Risk Committee authorized to set their remuneration.
• Shareholders will vote on the approval of the Alkermes plc 2018 Stock Option and Incentive Plan, as amended, which includes an increase in authorized shares.
• The board's authority to allot and issue shares under Irish law will be renewed for 18 months.
• The board's authority to disapply statutory pre-emption rights under Irish law will also be renewed for 18 months, subject to shareholder approval.
• The company reported strong 2025 performance, exceeding revenue and profitability guidance, with total revenues of approximately $1.48 billion and Adjusted EBITDA of $394 million.
• Key pipeline advancements include positive Phase 2 results for alixorexton in narcolepsy and initiation of Phase 1 studies for ALKS 4510 and ALKS 7290.
• The company completed the acquisition of Avadel Pharmaceuticals plc in February 2026, accelerating its entry into the sleep medicine market.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance exceeding guidance, significant pipeline advancements, and a strategic acquisition that positions the company for future growth.

Positives

• Exceeded 2025 revenue guidance by over $40 million, generating approximately $1.48 billion in total revenues.
• Achieved proprietary product net sales of approximately $1.2 billion, a 9% year-over-year increase.
• VIVITROL net sales increased 2% year-over-year to approximately $468 million.
• LYBALVI net sales increased 24% year-over-year to approximately $347 million.
• ARISTADA net sales increased 7% year-over-year to $370 million.
• Generated GAAP net income of approximately $242 million and Adjusted EBITDA of $394 million.
• Increased total cash, cash equivalents, restricted cash, and investments by approximately $495 million year-over-year.
• Successfully advanced alixorexton through Phase 2 studies for narcolepsy and obtained FDA Breakthrough Therapy designation.
• Completed the strategic acquisition of Avadel Pharmaceuticals plc, enhancing the commercial portfolio and accelerating entry into the sleep medicine market.
• Strong corporate governance practices are highlighted, with an independent board and active shareholder engagement.

Negatives

• The filing does not explicitly mention any negative financial or operational results.
• While the company exceeded financial guidance, the specific details of future financial performance are not provided in this proxy statement.

Risks

• The company's success depends on its ability to develop and commercialize new medicines, which involves significant R&D investment and inherent risks.
• Competition in the biopharmaceutical industry is intense, and the company faces competition from other companies developing similar treatments.
• The company's ability to achieve its strategic objectives, including the successful integration of Avadel and the development of its pipeline candidates, is subject to various risks and uncertainties.
• The company is subject to extensive government regulation, and changes in regulatory requirements or failure to comply could adversely affect its business.
• The company's reliance on third-party manufacturers for certain products and components could expose it to supply chain disruptions or quality issues.

Future Outlook

The company exceeded its 2025 objectives, demonstrating strong commercial performance, pipeline advancement, and profitability. The acquisition of Avadel is expected to accelerate entry into the sleep medicine market. The company is focused on continuing its growth and development in neuroscience disorders.

Management Comments

• "Alkermes mission is to pursue great science with deep compassion to make a real impact on people living with complex psychiatric and neurological disorders."
• "As a result of our employees hard work and dedication, we achieved significant milestones across all aspects of our business in 2025."
• "I cannot think of a time when Alkermes has been in a stronger position, poised for its next stage of growth."
• "I have great confidence in Blair's leadership and the progress we expect to make in the years ahead."
• "We are committed to operating and growing our business in a sustainable and responsible manner that promotes transparent governance and strong ethics."

Industry Context

StockSavvy.ai notes that Alkermes' focus on neuroscience, particularly its orexin 2 receptor agonist program for narcolepsy and idiopathic hypersomnia, aligns with a growing interest in treatments for sleep disorders. The acquisition of Avadel is a strategic move to capitalize on this market trend and leverage existing commercial infrastructure.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are being asked to vote on key corporate matters, including director elections and compensation, which directly impact their investment.
• Employees will be affected by the CEO transition and the continued integration of Avadel, potentially leading to new opportunities and operational changes.
• Patients will benefit from the advancement of the company's pipeline, particularly in neuroscience and sleep medicine, with potential new treatments.

Next Steps

• Shareholders to vote on the proposed resolutions at the 2026 Annual General Meeting.
• Richard F. Pops to retire as CEO on July 31, 2026, with Blair Jackson to assume the CEO role on August 1, 2026.
• Richard F. Pops will continue to serve as non-executive Chairman and Senior Advisor.
• Integration of Avadel Pharmaceuticals plc into Alkermes' operations.

Key Dates

Recommendation

The company is performing well and has a promising pipeline, but the upcoming CEO transition introduces a period of change. While the acquisition of Avadel is a positive strategic move, the full impact of integration and pipeline development needs to be monitored. A 'hold' recommendation reflects a balanced view of current strengths and future uncertainties.

Keywords

Alkermes plc, Proxy Statement, Annual General Meeting, Director Election, Executive Compensation, Auditor Ratification, Stock Option Plan, Irish Law, Shareholder Vote, Biopharmaceutical, Neuroscience, Narcolepsy, Alixorexton, Avadel Acquisition